Research Progress of EGFR Mutations in Lung Cancer and Targeted Drug Resistance Mechanisms

Qian Lu; Bian Li

Article Contents

Article Navigation > Journal of Kunming Medical University > 2017 > 38(08): 126-129

Qian Lu , Bian Li . Research Progress of EGFR Mutations in Lung Cancer and Targeted Drug Resistance Mechanisms[J]. Journal of Kunming Medical University, 2017, 38(08): 126-129.

Citation:

Qian Lu , Bian Li . Research Progress of EGFR Mutations in Lung Cancer and Targeted Drug Resistance Mechanisms[J]. Journal of Kunming Medical University, 2017, 38(08): 126-129.

Qian Lu , Bian Li . Research Progress of EGFR Mutations in Lung Cancer and Targeted Drug Resistance Mechanisms[J]. Journal of Kunming Medical University, 2017, 38(08): 126-129.

Citation:

Qian Lu , Bian Li . Research Progress of EGFR Mutations in Lung Cancer and Targeted Drug Resistance Mechanisms[J]. Journal of Kunming Medical University, 2017, 38(08): 126-129.

PDF( 182 KB)

Research Progress of EGFR Mutations in Lung Cancer and Targeted Drug Resistance Mechanisms

Qian Lu ,
Bian Li

Funds:

基金：国家自然科学基金资助项目 (81460355);

Received Date: 2017-05-14

Abstract

Abstract

EGFR mutations are closely associated with lung cancer development, this paper introduces the effectiveness of tyrosine kinase inhibitors on different epidermal growth factor receptor mutations and reviews the research progress of targeted drug resistance mechanisms, the aim is to further guide clinical targeted drugs.
- Epidermal growth factor receptor,
- Non-small cell lung cancer,
- Tyrosine kinase inhibitors

FullText(HTML)

References(15)

References

[1]	[1]FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136 (5) :359-386.
[2]周清华, 孙燕.加强我国肺癌分子靶向治疗基础和临床研究[J].中国肺癌杂志, 2004, 7 (4) :267-269.
[3]	[3]BALAK M N, GONG Y, RIELY G J, et al.Novel d761y and common secondary t790m mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors[J].Clin Cancer Res, 2006, 12 (21) :6494-6501.
[4]	[4]CHIU C H, YANG C T, SHIH J Y, et al.Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I Mutations[J].Journal of Thoracic Oncology, 2015, 10 (5) :796-797.
[5]	[5]KANCHA R K, VON BUBNOFF N, PESCHEL C, et al.Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy[J].Clin Cancer Res, 2009, 15 (2) :460-467.
[6]	[6]ROBERTS P J, STINCHCOMBE T E, DER C J.Personalized medicine in non small cell lung cancer:is KRAS a useful maker in selecting patients for epidemal growth factor receptor targeted therapy[J].Clin Oncol, 2010, 14 (20) :69-77.
[7]	[7]HELLMAN M D, REVA B, YU H, RUSCH V, et al.Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib[J].Journal of Thoracic Oncology, 2014, 10 (9) :73-74.
[8]	[8]AKITOHATA M D, HIROSHIGE YOSHIOKA M D, SHIRO FUJITA, et al.Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer[J].Journal of Thoracic Oncology, 2010, 10 (5) :1524-1528.
[9]	[9]JENN-YU W U, CHONG-JEN Y U, YEUN-CHUNG CHANG, et al.Effectiveness of Tyrosine Kinase Inhibitors on"Uncommon"Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer[J].Clin Cancer Res, 2011, 17 (11) :3812-3821.
[10]	[10]WU Y L, LEE J S, THONGPRASERT S, et al.Intercalated combination of chemotherapy and erlotinib for patients with Advanced stage non-small-cell lung cancer (FASTACT-2) :A randomised, double-blind trial[J].Lancet Oncol, 2013, 14 (8) :1-10.
[11]李静, 武新虎, 刘志冰, 等.阿法替尼联合西妥昔单抗治疗非小细胞肺癌EGFR T790M突变所致的吉非替尼耐药[J].肿瘤, 2013, 33 (7) :619.
[12]	[12]BUTTS C A, BODKIN D, MIDDLEMN E L, et al.Randomized phase II study of gemcitabine plus cisplatin with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol, 2007, 25 (36) :5777-5784.
[13]	[13]ROSELL R, ROBINET G, SZCZESNA A, et al.Randomized phaseⅡsutdy of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer[J].Ann Oncol, 2008, 19 (2) :362-369.
[14]	[14]KIM E S, NEUBAUER M, COHN A, et al.Docetaxel or pemetrexed with or Without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy:A phase3, open-label, Randomised trial[J].Lancet Oncol, 2013, 14 (13) :1326-1336.
[15]	[15]KOBAYASHI S, JI H, YUZA Y, et al.An alternative inhibitor overcomes esistance caused by a mutation of the epidemal growth factor receptor[J].Cancer Res, 2005, 65 (16) :7096-7001.

Relative Articles(20)

Relative Articles

[1]	Shengxi YANG, Jiade ZHU, Qiurui LI, Wenlian TU. Clinical Study of Aumolertinib Versus Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Journal of Kunming Medical University, 2025, 46(5): 89-95. doi: 10.12259/j.issn.2095-610X.S20250510
[2]	Yiduo XU, Yanqi ZHOU, Jian WANG, Jiang LONG. Studies on the Role of S100A9-RAGE/TLR4 Signaling Axis in Regulating Brain Metastasis and Endothelial Adhesion of Non-Small Cell Lung Cancer. Journal of Kunming Medical University, 2025, 46(9): 23-36. doi: 10.12259/j.issn.2095-610X.S20250903
[3]	Huimin YU, Xin XIN, Zhiwei LIANG. Predictive Value of KIAA1199 and Linc00673 Genes on Chemotherapy Efficacy in Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2025, 46(1): 111-116. doi: 10.12259/j.issn.2095-610X.S20250115
[4]	Yingfu LI, Ni GUO, Zhengguang LUO, Anhao XING, Taifu LI, Qianli MA. Correlation of EGFR Gene Polymorphisms with Non-small Cell Lung Cancer in Yunnan Han Population. Journal of Kunming Medical University, 2025, 46(4): 99-108. doi: 10.12259/j.issn.2095-610X.S20250413
[5]	Yueting YAO, Shuai LI, Yang CAO, Mu LIN, Zhengguang LUO, Xiaobo CHEN, Qianli MA. Correlation between Epidermal Growth Factor Gene Polymorphisms and Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2025, 46(9): 89-97. doi: 10.12259/j.issn.2095-610X.S20250910
[6]	Caini ZHANG, Ya LI. A Meta-analysis of the Efficacy and Safety of Camrelizumab Combined with Chemotherapy in the Treatment of Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2024, 45(6): 75-84. doi: 10.12259/j.issn.2095-610X.S20240610
[7]	Chao HONG, Xudong XIANG, Yingfu LI, Yang CAO, Xueya CHEN, Shuai LI, Anhao XING, Mu LIN, Qianli MA. Association of Polymorphisms in the 3' UTR of Genes in the ERK1/2 Signaling Pathway with Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2024, 45(3): 7-17. doi: 10.12259/j.issn.2095-610X.S20240302
[8]	Yan LIANG, Lei WANG, Ming LEI, Benchao CHEN, Ping SUN, Shuai LI, Li LIU, Qianrong WANG, Manlin LIAO, Qianli MA. Correlation between KRAS Gene Polymorphism and Non-small Cell Lung Cancer in Yunnan Han Population. Journal of Kunming Medical University, 2023, 44(2): 52-60. doi: 10.12259/j.issn.2095-610X.S20230210
[9]	Chuntao LI, Xuemei ZHANG, Yandi SU, Jianqing Zhang. Construction of Stable Transfected Cell Line A549 of Non-small Cell Lung Cancer by Overexpressing and Knocking Down LncRNA RP11-521C20.3. Journal of Kunming Medical University, 2023, 44(10): 1-9. doi: 10.12259/j.issn.2095-610X.S20231016
[10]	Maofang WU, Yongchun ZHOU, Jingjing CAI, Xin MO, Yinwei LI, Jiahui MAO. EGFR Gene Mutation State and Its Clinical Significance in Multi-nodular Lung Adenocarcinoma in Yunnan Province. Journal of Kunming Medical University, 2022, 43(2): 60-66. doi: 10.12259/j.issn.2095-610X.S20220215
[11]	Jia YANG, Ya-xian LI, Ying-ying WANG, Lin XIAO, Chuan-yin LI, Fang TAN, Qian-li MA, Shu-yuan LIU. Association of the miR-149,miR-219 and miR-let-7 Polymorphisms with the Occurrence and Development of Non-small Cell Lung Cancer in a Chinese Han Population in Yunnan Province. Journal of Kunming Medical University, 2021, 42(10): 22-28. doi: 10.12259/j.issn.2095-610X.S20211037
[12]	Ying-xia WANG, Qin HE, Guo-fang WANG, Xuan ZHANG. Expression and Significance of microRNA-21 and EGFR in Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2021, 42(8): 101-105. doi: 10.12259/j.issn.2095-610X.S20210818
[13]	Xiao-biao MA, Feng LUO, Yong-liang GAO, Jing-chao HAO. Clinical Study of Chemotherapy Combined with CIK Cell Immunotherapy for Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2020, 41(12): 60-67. doi: 10.12259/j.issn.2095-610X.S20201215
[14]	Chen Ben Chao , Li Heng , Liu Chao , Wang Shu Ting , Li Gao Feng . . Journal of Kunming Medical University, 2020, 41(06): 23-27.
[15]	Wang Juan , Su Guo Miao , Pan Guo Qing , Bian Li , Yang Zhe , Zeng Ding Tao . . Journal of Kunming Medical University, 2020, 41(09): 1-6.
[16]	Tang Shi Cong , Pan Hong , Huang Yao Yuan , Zhou Xin , Wang Shou Feng , Zuo Chuan Tian , Mao Nai Quan . . Journal of Kunming Medical University, 2017, 38(02): 28-32.
[17]	Zhong Fang Fang . . Journal of Kunming Medical University,
[18]	Zhou JieYan . . Journal of Kunming Medical University,
[19]	Yang Fang . . Journal of Kunming Medical University,
[20]	Zhang Lan Feng . . Journal of Kunming Medical University,